BACKGROUND:Thalidomide maintenance therapy after stem cell transplantation resulted in increased progression-free survival and overall survival in a few trials, but its role in non-transplant eligible patients with multiple myeloma remains unclear. This study assessed the impact of thalidomide-interferon in comparison to interferon maintenance therapy in elderly patients with multiple myeloma. DESIGN AND METHODS: Of 289 elderly patients with multiple myeloma who were randomized tothalidomide-dexamethasone or melphalan-prednisolone induction therapy, 137 finally completed 9 cycles of induction therapy with stable disease or better and thereby qualified for maintenance treatment. Of these, 128 have been randomized to either thalidomide-interferon or interferon alone. Primary study endpoints were progression-free survival and response rates; secondary endpoints were overall survival, toxicity and quality of life. RESULTS:Thalidomide-interferon maintenance therapy led to a significantly longer progression-free survival compared to interferon (27.7 vs. 13.2 months, P=0.0068), but overall survival was similar in both groups (52.6 vs. 51.4 months, P=0.81) and did not differ between patients aged 75 years or older, or younger patients (P=0.39). Survival after disease progression tended to be shorter in patients on thalidomide-interferon maintenance therapy (P=0.056). Progression-free survival and overall survival tended to be shorter in patients with adverse cytogenetic (FISH) findings compared to the standard risk group but differences were not significant (P=0.084 and P=0.082, respectively). Patients on thalidomide-interferon presented with more neuropathy (P=0.0015), constipation (P=0.0004), skin toxicity (P=0.0041) and elevated creatinine (P=0.026). CONCLUSIONS:Thalidomide plus interferon maintenance therapy increased progression-free survival but not overall survival and was associated with slightly more toxicity than maintenance with interferon alone. (ClinicalTrials.gov Identifier: NCT00205751).
RCT Entities:
BACKGROUND:Thalidomide maintenance therapy after stem cell transplantation resulted in increased progression-free survival and overall survival in a few trials, but its role in non-transplant eligible patients with multiple myeloma remains unclear. This study assessed the impact of thalidomide-interferon in comparison to interferon maintenance therapy in elderly patients with multiple myeloma. DESIGN AND METHODS: Of 289 elderly patients with multiple myeloma who were randomized to thalidomide-dexamethasone or melphalan-prednisolone induction therapy, 137 finally completed 9 cycles of induction therapy with stable disease or better and thereby qualified for maintenance treatment. Of these, 128 have been randomized to either thalidomide-interferon or interferon alone. Primary study endpoints were progression-free survival and response rates; secondary endpoints were overall survival, toxicity and quality of life. RESULTS:Thalidomide-interferon maintenance therapy led to a significantly longer progression-free survival compared to interferon (27.7 vs. 13.2 months, P=0.0068), but overall survival was similar in both groups (52.6 vs. 51.4 months, P=0.81) and did not differ between patients aged 75 years or older, or younger patients (P=0.39). Survival after disease progression tended to be shorter in patients on thalidomide-interferon maintenance therapy (P=0.056). Progression-free survival and overall survival tended to be shorter in patients with adverse cytogenetic (FISH) findings compared to the standard risk group but differences were not significant (P=0.084 and P=0.082, respectively). Patients on thalidomide-interferon presented with more neuropathy (P=0.0015), constipation (P=0.0004), skin toxicity (P=0.0041) and elevated creatinine (P=0.026). CONCLUSIONS:Thalidomide plus interferon maintenance therapy increased progression-free survival but not overall survival and was associated with slightly more toxicity than maintenance with interferon alone. (ClinicalTrials.gov Identifier: NCT00205751).
Authors: James R Berenson; John J Crowley; Thomas M Grogan; Jeffrey Zangmeister; Adrienne D Briggs; Glenn M Mills; Bart Barlogie; Sydney E Salmon Journal: Blood Date: 2002-05-01 Impact factor: 22.113
Authors: Henk M Lokhorst; Bronno van der Holt; Sonja Zweegman; Edo Vellenga; Sandra Croockewit; Marinus H van Oers; Peter von dem Borne; Pierre Wijermans; Ron Schaafsma; Okke de Weerdt; Shulamiet Wittebol; Michel Delforge; Henriëtte Berenschot; Gerard M Bos; Kon-Siong G Jie; Harm Sinnige; Marinus van Marwijk-Kooy; Peter Joosten; Monique C Minnema; Rianne van Ammerlaan; Pieter Sonneveld Journal: Blood Date: 2009-10-30 Impact factor: 22.113
Authors: Bart Barlogie; Guido Tricot; Elias Anaissie; John Shaughnessy; Erik Rasmussen; Frits van Rhee; Athanasios Fassas; Maurizio Zangari; Klaus Hollmig; Mauricio Pineda-Roman; Choon Lee; Giampaolo Talamo; Raymond Thertulien; Elias Kiwan; Somashekar Krishna; Michele Fox; John Crowley Journal: N Engl J Med Date: 2006-03-09 Impact factor: 91.245
Authors: J Bladé; D Samson; D Reece; J Apperley; B Björkstrand; G Gahrton; M Gertz; S Giralt; S Jagannath; D Vesole Journal: Br J Haematol Date: 1998-09 Impact factor: 6.998
Authors: Heinz Ludwig; Brian G M Durie; Philip McCarthy; Antonio Palumbo; Jésus San Miguel; Bart Barlogie; Gareth Morgan; Pieter Sonneveld; Andrew Spencer; Kenneth C Andersen; Thierry Facon; Keith A Stewart; Hermann Einsele; Maria-Victoria Mateos; Pierre Wijermans; Anders Waage; Meral Beksac; Paul G Richardson; Cyrille Hulin; Ruben Niesvizky; Henk Lokhorst; Ola Landgren; P Leif Bergsagel; Robert Orlowski; Axel Hinke; Michele Cavo; Michel Attal Journal: Blood Date: 2012-01-23 Impact factor: 22.113
Authors: H Ludwig; J S Miguel; M A Dimopoulos; A Palumbo; R Garcia Sanz; R Powles; S Lentzsch; W Ming Chen; J Hou; A Jurczyszyn; K Romeril; R Hajek; E Terpos; K Shimizu; D Joshua; V Hungria; A Rodriguez Morales; D Ben-Yehuda; P Sondergeld; E Zamagni; B Durie Journal: Leukemia Date: 2013-10-09 Impact factor: 11.528
Authors: Francesca Gay; Graham Jackson; Laura Rosiñol; Sarah A Holstein; Philippe Moreau; Stefano Spada; Faith Davies; Juan José Lahuerta; Xavier Leleu; Sara Bringhen; Andrea Evangelista; Cyrille Hulin; Ugo Panzani; David A Cairns; Francesco Di Raimondo; Margaret Macro; Anna Marina Liberati; Charlotte Pawlyn; Massimo Offidani; Andrew Spencer; Roman Hájek; Evangelos Terpos; Gareth J Morgan; Joan Bladé; Pieter Sonneveld; Jesús San-Miguel; Philip L McCarthy; Heinz Ludwig; Mario Boccadoro; Maria-Victoria Mateos; Michel Attal Journal: JAMA Oncol Date: 2018-10-01 Impact factor: 31.777
Authors: Antonio Palumbo; S Vincent Rajkumar; Jesus F San Miguel; Alessandra Larocca; Ruben Niesvizky; Gareth Morgan; Ola Landgren; Roman Hajek; Hermann Einsele; Kenneth C Anderson; Meletios A Dimopoulos; Paul G Richardson; Michele Cavo; Andrew Spencer; A Keith Stewart; Kazuyuki Shimizu; Sagar Lonial; Pieter Sonneveld; Brian G M Durie; Philippe Moreau; Robert Z Orlowski Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: P Leif Bergsagel; María-Victoria Mateos; Norma C Gutierrez; S Vincent Rajkumar; Jesús F San Miguel Journal: Blood Date: 2012-11-19 Impact factor: 22.113
Authors: Yucai Wang; Fang Yang; Yan Shen; Wenwen Zhang; Jacqueline Wang; Victor T Chang; Borje S Andersson; Muzaffar H Qazilbash; Richard E Champlin; James R Berenson; Xiaoxiang Guan; Michael L Wang Journal: J Natl Cancer Inst Date: 2015-11-18 Impact factor: 13.506